Tag: EMA

Mitigating Risks of Unreported API Changes During Dossier Submission In the pharmaceutical landscape, the integrity of the Active Pharmaceutical Ingredient (API) dossier is paramount. However, discrepancies such as API change…

CAPA Expectations for Reporting API Changes During Inspection Preparation In the pharmaceutical manufacturing landscape, the accuracy of documentation and communication regarding Active Pharmaceutical Ingredient (API) changes is crucial, especially during…

Enhancing CAPA Effectiveness During Requalification to Address Documentation Gaps The challenge of ensuring CAPA effectiveness during requalification is a persistent issue that can lead to significant regulatory scrutiny. With the…

Addressing Stability Data Gaps During Inspection: An Actionable Playbook In the world of pharmaceutical manufacturing and quality systems, maintaining robust stability data during inspection preparation is vital. Regulatory agencies such…

Addressing Deviation Histories During Requalification: A Playbook for Compliance and Quality Assurance Deviation histories play a critical role in ensuring compliance with Good Manufacturing Practices (GMP) and maintaining rigorous quality…

Addressing Gaps in Stability Data During Requalification for Manufacturing Readiness In the highly regulated pharmaceutical industry, maintaining manufacturing readiness is essential for compliance with GMP standards. One critical area often…

Addressing Deviation History During Dossier Submission to Prevent PQ Suspension Pharmaceutical organizations often face challenges with deviations that arise during the manufacturing process or quality control, particularly when submitting dossiers…

Defending Manufacturing Readiness Amidst Concerns Over CAPA Effectiveness During Requalification In the continually evolving landscape of pharmaceutical manufacturing, ensuring compliance with Good Manufacturing Practices (GMP) and maintaining a robust Quality…

“`html Addressing Gaps in Stability Data During Dossier Submission to Prevent PQ Suspension In the pharmaceutical industry, the integrity of stability data is paramount during dossier submissions for WHO Prequalification…

“`html Addressing Stability Data Gaps During Dossier Submission for Regulatory Review In the complex landscape of pharmaceutical regulatory submissions, one common contention that businesses must navigate is the prevalence of…

Addressing Unreported API Changes During Inspection Preparation: A Comprehensive Playbook In the ever-evolving landscape of pharmaceutical manufacturing, effective communication regarding Active Pharmaceutical Ingredient (API) changes is crucial for maintaining compliance…

Addressing PQ Dossier Deficiencies during WHO PQ Assessments: A Comprehensive Playbook for Pharma Professionals In today’s rapidly evolving pharmaceutical landscape, ensuring compliance with regulatory frameworks like the World Health Organization…